These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 31166081

  • 1. The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension.
    Ruan H, Zhang Y, Liu R, Yang X.
    Congenit Heart Dis; 2019 Jul; 14(4):645-650. PubMed ID: 31166081
    [Abstract] [Full Text] [Related]

  • 2. Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects.
    Xiao JW, Zhu XY, Wang QG, Zhang DZ, Cui CS, Zhang P, Chen HY, Meng LL.
    Circ J; 2015 Jul; 79(6):1342-8. PubMed ID: 25797071
    [Abstract] [Full Text] [Related]

  • 3. [Acute effects of intravenous fasudil with different dosage on patients with congenital heart defects and severe pulmonary arterial hypertension].
    Ruan HY, Zhang YG, Liu R.
    Zhonghua Yi Xue Za Zhi; 2018 Mar 06; 98(9):678-681. PubMed ID: 29534403
    [Abstract] [Full Text] [Related]

  • 4. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease.
    Li F, Xia W, Yuan S, Sun R.
    Pediatr Cardiol; 2009 Apr 06; 30(3):363-6. PubMed ID: 18953591
    [Abstract] [Full Text] [Related]

  • 5. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.
    Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H.
    Heart Vessels; 2010 Mar 06; 25(2):144-9. PubMed ID: 20339976
    [Abstract] [Full Text] [Related]

  • 6. Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs.
    Hanson SFL, Terry MH, Moretta DT, Power GG, Wilson SM, Alam F, Ahsan F, Blood AB, Giri PC.
    J Cardiovasc Pharmacol Ther; 2018 Sep 06; 23(5):472-480. PubMed ID: 29756460
    [Abstract] [Full Text] [Related]

  • 7. Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study.
    Jiang X, Wang YF, Zhao QH, Jiang R, Wu Y, Peng FH, Xu XQ, Wang L, He J, Jing ZC.
    Int J Cardiol; 2014 Nov 15; 177(1):61-5. PubMed ID: 25499341
    [Abstract] [Full Text] [Related]

  • 8. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY, Li QQ, Zhang C, Zhang HS, Gu H.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr 24; 48(4):315-322. PubMed ID: 32370483
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study.
    Zhang X, Zhang X, Wang S, Luo J, Zhao Z, Zheng C, Shen J.
    Can Respir J; 2018 Apr 24; 2018():3148259. PubMed ID: 29785232
    [Abstract] [Full Text] [Related]

  • 12. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension.
    Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, Nakano T.
    Circ J; 2006 Feb 24; 70(2):174-8. PubMed ID: 16434811
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease.
    Apostolopoulou SC, Rammos S, Kyriakides ZS, Webb DJ, Johnston NR, Cokkinos DV, Kremastinos DT.
    Heart; 2003 Oct 24; 89(10):1221-6. PubMed ID: 12975426
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response.
    Cannon BC, Feltes TF, Fraley JK, Grifka RG, Riddle EM, Kovalchin JP.
    Pediatr Cardiol; 2005 Oct 24; 26(5):565-9. PubMed ID: 16132310
    [Abstract] [Full Text] [Related]

  • 17. The Therapeutic Role of Rho Kinase Inhibitor, Fasudil, on Pulmonary Hypertension; a Systematic Review and Meta-Analysis.
    Abedi F, Omidkhoda N, Arasteh O, Ghavami V, Hosseinzadeh H.
    Drug Res (Stuttg); 2023 Jan 24; 73(1):5-16. PubMed ID: 36216340
    [Abstract] [Full Text] [Related]

  • 18. [Effects of iloprost combined with low dose tadalafil in adult congenital heart disease patients with severe pulmonary arterial hypertension: a single-center, open-label controlled study].
    Zhang C, Huang Y, Huang T, Xia C, Huang X, Zhang G, Yao H, Chen J, Chen J, Wu S, Zhuang J.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Jun 24; 42(6):474-80. PubMed ID: 25164220
    [Abstract] [Full Text] [Related]

  • 19. Effects of fasudil on pulmonary hypertension in clinical practice.
    Zhang Y, Wu S.
    Pulm Pharmacol Ther; 2017 Oct 24; 46():54-63. PubMed ID: 28782712
    [Abstract] [Full Text] [Related]

  • 20. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
    Jiang BH, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H.
    J Cardiovasc Pharmacol; 2007 Feb 24; 49(2):85-9. PubMed ID: 17312448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.